Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROWAN: TheraSphere Followed by Durvalumab and Tremelimumab for HCC
NCT05063565Phase 2Active, not recruiting
- Sponsor
- Boston Scientific Corporation
- Start
- Nov 2023
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 5
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in hepatocellular carcinoma (HCC), sponsored by Boston Scientific Corporation. Started Nov 2023; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05063565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063565.